Loading…

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

Saved in:

Bibliographic Details
Published in:	Leukemia 2016-04, Vol.30 (4), p.995-998
Main Authors:	Kumar, S K, Ma, E, Engebretson, A E, Buadi, F K, Lacy, M Q, Dispenzieri, A, Duh, M S, Lafeuille, M-H, Lefebvre, P, Cheng, W Y, Dea, K, Rembert, D, Patt, D, Niculescu, L, Quick, M, Rajkumar, S V
Format:	Article
Language:	English
Subjects:	631/67 692/308/409 692/699/67/1990/804 692/700 692/700/3934 Antineoplastic Combined Chemotherapy Protocols - economics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bortezomib Bortezomib - administration & dosage Cancer Research Cost benefit analysis Critical Care Medicine Cyclophosphamide Cyclophosphamide - administration & dosage Development and progression Dexamethasone Dexamethasone - administration & dosage Drug therapy Economic aspects Follow-Up Studies Health Care Costs - statistics & numerical data Health Resources - utilization Hematology Humans Intensive Internal Medicine letter-to-the-editor Medicine Medicine & Public Health Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Multiple Myeloma - economics Multiple Myeloma - mortality Neoplasm Staging Oncology Patient outcomes Prognosis Resource utilization Survival Rate Thalidomide - administration & dosage Thalidomide - analogs & derivatives
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!